Finnrick, an independent testing programme, publishes 59 assays for BeiBangAn: 43 met its Purity focus threshold (at least 99.5% purity, no more than 35% dosage deviation) and 15 did not. Most recent assay 4 Aug 2026.
BeiBangAn operates from china, listed by Finnrick as "Trading", has no storefront on record — Finnrick lists only a messaging or social contact. Source: Finnrick, https://www.finnrick.com/vendors/beibangan.
Finnrick-tested with poor results. Tested across 2 peptide products with 42 total samples.
BeiBangAn is listed as active. Finnrick Grade D. Finnrick avg score: 7/10 across 42 samples (2 products). Below-average quality. Exercise caution.
BeiBangAn holds independent lab grade D, assigned across 42 graded samples, average score 7/10. That grade comes from an independent grader's own sampling, not from PeptideAtlas, and it describes the samples that grader obtained rather than every batch sold.
No independent third-party assay is on file for BeiBangAn, and we have not yet compiled a profile of its own website. An untested vendor has not failed a test — this is an absence of evidence, not evidence against it.
| Product | Assays | Result |
|---|---|---|
| Retatrutide | 32 | 22 passed, 9 failed |
| Tirzepatide | 18 | 14 passed, 4 failed |
| GHK-Cu | 5 | 4 passed, 1 failed |
| BPC-157 | 4 | 3 passed, 1 failed |
Source: Finnrick, as published 2026-08-09. Pass and fail are Finnrick's classification against its own threshold, not ours.
| Status | Active |
|---|---|
| Independent lab grade | D (42 samples) |
| Average grader score | 7/10 |
| Vendor type | Research-use supplier |
BeiBangAn is listed as active and we hold 59 Finnrick assays (43 passing, 15 failing its purity threshold); an independent lab grade of D. That is evidence about the batches that were tested or published, not a guarantee about the vial you receive.
Yes. Finnrick, an independent testing programme, publishes 59 assays for BeiBangAn: 43 met its Purity focus threshold (at least 99.5% purity, no more than 35% dosage deviation) and 15 did not. Most recent assay 4 Aug 2026.
Similar vendors: SwissChems, Bfflink, Reta-Peptide, HkRoids, Zenith Jove Peptide ZJ, Shanghai Baoju, Heman Peptide HM, Allen Biotechnology Co ABC.
Popular peptides: Semaglutide, Tirzepatide, Retatrutide, BPC-157, CJC-1295, Ipamorelin.
Other reviewed vendors: Beligas Pharmaceuticals Peptides Review, Beligas pharmacy Peptides Review, benelux-pharma.com Peptides Review.